General form of registration statement for all companies including face-amount certificate companies

Intangible Asset (Details Narrative)

v3.10.0.1
Intangible Asset (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Jun. 30, 2018
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Capitalized cost     $ 3,037,147 $ 3,037,147      
Business combination of tax basis     1,782 $ 1,782      
Number of shares acquired in exchange for common stock   31,745,242   2,090,301      
Precentage of issued and outstanding common stock diluted basis   90.00%          
Proceeds from common stock       $ 2,856,073 $ 4,270,000
Amortization expense     197,124 $ 222,559    
Weighted average amortization period for intangible asset       14 years      
Future amortization expense, twelve months     788,495 $ 788,495      
Future amortization expense, year two     788,495 788,495      
Future amortization expense, year three     788,495 788,495      
Future amortization expense, year four     788,495 788,495      
Future amortization expense, year five     788,495 788,495      
Subscription Receivable [Member]              
Proceeds from royalty receivable       8,000,000      
CoNCERT Pharmaceuticals, Inc [Member]              
Capitalized cost     11,038,929 11,038,929      
Transaction costs     $ 1,782 $ 1,782      
Option exercised in exchange for common stock $ 8,000,000            
Number of shares acquired in exchange for common stock 2,090,301            
Percentage of common stock holdings 6.58%            
Precentage of issued and outstanding common stock diluted basis 5.93%            
Percentage of royalty 15.00%            
Proceeds from royalty receivable $ 8,000,000            
Proceeds from common stock $ 8,000,000